Department of Radiotherapy, Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
Department of Radiotherapy, Ospedale Civile Maggiore, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Anticancer Res. 2020 Oct;40(10):5901-5907. doi: 10.21873/anticanres.14610.
BACKGROUND/AIM: To assess predictors of local control (LC) for stereotactic ablative radiotherapy (SAbR) in pulmonary oligometastatic disease (OMD) from gastrointestinal (GI) malignancies.
Patients with pulmonary OMD treated with SAbR from January 2016 to December 2018 were included in this observational analysis. Primary endpoint was LC. Uni- and multivariate analyses to assess variable correlations were conducted.
Thirty-seven patients and 59 lung metastases were evaluated. The delivered dose was 30-60 Gy in 3-8 fractions. After a median follow-up of 23.0 months (range=6.3-50.4 months), LC rate at 1/2 years was 89.7%/85.0%, and increased to 96.0%/91.0% for lesions treated with a biologically effective dose (BED) ≥100 Gy (p=0.03). RECIST response at 6 months was predictive for LC (p=0.002).
SAbR is an effective option for pulmonary OMD from GI malignancies. A BED ≥100 Gy and radiological response at 6 months can affect LC.
背景/目的：评估胃肠道（GI）恶性肿瘤肺寡转移疾病（OMD）患者接受立体定向消融放疗（SAbR）的局部控制（LC）的预测因素。
本观察性分析纳入了 2016 年 1 月至 2018 年 12 月接受 SAbR 治疗的肺 OMD 患者。主要终点为 LC。进行单变量和多变量分析以评估变量相关性。
共评估了 37 名患者和 59 个肺转移灶。给予 30-60Gy 的剂量，分 3-8 次给予。中位随访 23.0 个月（范围 6.3-50.4 个月）后，1/2 年 LC 率分别为 89.7%/85.0%，而生物有效剂量（BED）≥100Gy 的病变 LC 率分别增至 96.0%/91.0%（p=0.03）。6 个月时的 RECIST 反应可预测 LC（p=0.002）。
SAbR 是胃肠道恶性肿瘤肺寡转移疾病的有效治疗方法。BED≥100Gy 和 6 个月时的放射学反应可能会影响 LC。
Zotero 插件